FDA eyes criminal charge against execs for off-label marketing

10/14/2010 | Bloomberg

The FDA is considering bringing a misdemeanor charge against executives of pharmaceutical companies that promote treatments for off-label use, said Eric Blumberg, the agency's deputy chief for litigation. "Unless the government shows more resolve to criminally charge individuals at all levels in the company, we cannot expect to make progress in deterring off-label promotion," Blumberg said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT